1 May 2020
Leading paediatricians in the UK have set out a working definition of an inflammatory syndrome affecting a very small number of children and which may be associated with COVID-19.
27 April 2020
Following reports of a small number of cases of a COVID-19 related condition emerging in children, our President has made a statement.
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
13 March 2020
Russell updates members on how the College is responding to COVID-19. In this message, which has been emailed to all members, he outlines the College's actions towards COVID-19 and highlights advice and guidance for our members.
2 March 2020
The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.
19 February 2020
Russell has been speaking with quite a few members about COVID-19, also known as the novel coronavirus. In this message, which has been emailed to all members, he outlines what we know and how the situation is affecting the RCPCH.
5 February 2020
Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.
27 January 2020
This British Paediatric Surveillance Unit study will aim to gain a better understanding of these non-vaccine strains of pneumococcal bacteria causing meningitis - enabling more accurate information to patients and their families on prognosis and informing public health vaccine policy.
16 December 2019
Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg because of a lack of evidence for benefit.
16 October 2019
Withdrawal and Medicines Alerts for Ranitidine Related Products Zantac®, used to treat conditions such as acid reflux in children, has been recalled by its manufacturer because of concerns that it may contain low levels of NDMA.